PATENT ATTORNEY DOCKET NO. 50319/003001

Certificate of Mailing: Date of Deposit: September 26, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Jeremy Waterman

Printed name of person mailing correspondence

ture of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Ribes et al.

Art Unit:

1614

Serial No.:

10/069,574

Examiner:

Kevin E. Weddington

Filed:

August 1, 2002

Customer No.:

21559

Title:

Use of Amino Acids for Making Medicines for Treating to Insulin-

Resistance

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: September 26, 2005

Susan M. Michaud, Ph.D.

Reg. No. 42,885

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045



KM PTO-1449

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Attorney Docket No.

50319/003001

Serial No.

10/069,574

Applicant

Ribes et al.

Filing Date

August 1, 2002

Group

1614

(37 C.F.R. § 1.98(b))

IDS Filed

September 26, 2005

Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)	
	FOR	EIGN PATENT OR	PUBLISHED FOREIGN PATENT	APPLICATION	DN .		
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)	
	OTHER DOC	CUMENTS (INCLUD	DING AUTHOR, TITLE, DATE, PL	ACE OF PUB	LICATION)		
<u>-</u>	1	ereochemistry of 4-	Hydroxyisoleucine From Trigonell			tochemistry	
	Bordia et al., "Effect of Ginger (Zingiber Officinale Rosc.) and Fenugreek (Trigonella Foenumgraecum L.) on Blood Lipids, Blood Sugar and Platelet Aggregation in Patients with Coronary Artery Disease," Prostaglandins, Leukotrienes and Essential Fatty Acids 56:379-384, 1997.						
	Broca et al., "4-Hydroxyisoleucine: Effects of Synthetic and Natural Analogues on Insulin Secretion," Eur. J. Pharmacol. 390:339-345, 2000. Fowden et al., "4-Hydroxyisoleucine from Seed of Trigonella Foenum-Graecum," Phytochemistry 12:1707-17:1973. Khosla et al., "Effect of Trigonella Foenum-Graecum (Fenugreek) on Blood Glucose in Normal and Diabetic Rats," Indian J. Physiol. Pharmacol. 39:173-174, 1995. Madar et al., "Glucose Lowering Effect of Fenugreek in Non-Insulin Dependent Diabetics," Eur. J. Clinical Nutrition 42:51-54, 1988. Neeraja et al., "Hypoglycemic Effect of Processed Fenugreek Seeds in Humans," J. Food Sci. Technol. 33:42 430, 1996.					tion," Eur. J.	
						y 12:1707-1711,	
						and Diabetic	
						J. Clinical	
						echnol. 33:427-	
	Ohnuma et al., "Anaphylaxis to Curry Powder," Allergy 53:452-454, 1998.						
	Patil et al., "Allergy to Fenugreek (Trigonella Foenum Graecum)," Ann. Allergy Asthma Immunol. 78:297-300, 1997.						
	Petit et al., "Ster	oid Saponins from	Fenugreek Seeds: Extraction, Puritholesterol," Steroids 60:674-680,	fication and l	Pharmacolog	ical Investigation	

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this		

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50319/003001
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/069,574
INICODAAATI	ON DISCLOSURE	Applicant	Ribes et al.
STATEMEN	ON DISCLOSURE T BY APPLICANT	Filing Date	August 1, 2002
(Use several sheets if necessary)		Group	1614
(37 C.F.R. § 1.98(b))		IDS Filed	September 26, 2005

Petit et al., "Effects of a Fenugreek Seed Extract on Feeding Behavior in the Rat: Metabolic-Endocrine Correlates," Pharmacol. Biochem. Behav. 45:369-374, 1993.
Prasanna, "Hypolipidemic Effect of Fenugreek: a Clinical Study," Indian J. Pharmacol. 32:34-36, 2000.
Ribes et al., "Antidiabetic Effects of Subfractions from Fenugreek Seeds in Diabetic Dogs," Proc. Soc. Exp. Biol. Med. 182:159-166, 1986.
Ribes et al., "Effect of Fenugreek Seeds on Endocrine Pancreatic Secretions in Dogs," Ann. Nutr. Metab. 28:37-43, 1984.
Ribes et al., "Hypocholesterolaemic and Hypotriglyceridaemic Effects of Subfractions from Fenugreek Seeds in Alloxan Diabetic Dogs," Phytotherapy Res. 1:38-43, 1987.
Sauvaire et al., "Implication of Steroid Saponins and Sapogenins in the Hypocholesterolemic Effect of Fenugreek," Lipids 26:191-197, 1991.
Sauvaire et al., "Changes in Growth, Proteins and Free Amino Acids of Developing Seed and Pod of Fenugreek," Phytochem. 23:479-486, 1984.
Sauvaire et al., "Chemistry and Pharmacology of Fenugreek," <u>Herbs, Botanicals & Teas</u> Eds. G. Mazza and B.D. Oomah, 107-129, 2000.
Sharma, "Effect of Fenugreek Seeds and Leaves on Blood Glucose and Serum Insulin Responses in Human Subjects," Nutrition Res. 6:1353-1364, 1986.
Sharma et al., "Hypoglycaemic Effect of Fenugreek Seeds in Non-Insulin Dependent Diabetic Subjects," Nutrition Res. 10:731-739, 1990.
Sharma et al., "Use of Fenugreek Seed Powder in the Management of Non-Insulin Dependent Diabetes Mellitus," Nutr. Res. 16:1331-1339, 1996.
Sharma et al., "Effect of Fenugreek Seeds on Blood Glucose and Serum Lipids in Type I Diabetes," Eur. J. Clin. Nutr. 44:301-306, 1990.
Sowmya et al., "Hypocholesterolemic Effect of Germinated Fenugreek Seeds in Human Subjects," Plant Foods Hum. Nutr. 53:359-365, 1999.
Valette et al., "Hypocholesterolaemic Effect of Fenugreek Seeds in Dogs," Atherosclerosis 50:105-111, 1984.
,

EXAMINER	DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this			

form with the next communication to applicant.